This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jones, D. Articles by Bellomo, R. Search for Related Content PubMed PubMed Citation Articles by Jones, D. Articles by Bellomo, R. Social Bookmarking                         What's this?

Renal-Dose Dopamine: From Hypothesis to Paradigm to Dogma to Myth and, Finally, Superstition?

Departments of Intensive Care and Department of Medicine (Melbourne University), Austin Hospital, Melbourne, Australia

Rinaldo Bellomo, MB, BS, FRACP, FJFICM

Departments of Intensive Care and Department of Medicine (Melbourne University), Austin Hospital, Melbourne, Australia, rinaldo.bellomo{at}austin.org.au

Acute renal failure (ARF) is common in the critically ill and is associated with a high mortality rate. Its pathogenesis is not understood. Because animal models use ischemia to induce experimental ARF, there is the widespread belief that lack of blood flow is responsible for ARF. Low-dose dopamine (LDD) has been shown to increase renal blood flow in animal and in human volunteers. Thus, it has been administered to humans for almost 3 decades in the belief that it would lead to renal arterial vasodilation and increase renal blood flow (RBF). However, the etiology of ARF in critical illness is likely multifactorial, and the contribution of hypovolemia and reduced renal perfusion is unknown. Furthermore, interindividual variation in the pharmacokinetics of dopamine typically results in poor correlation between blood levels and administered dose, making accurate and reliable delivery of LDD difficult. Finally, dopamine is a proximal tubular diuretic that increases Na⁺ delivery to tubular cells, thus increasing their oxygen demands. Accordingly, even if LDD were able to preferentially increase RBF, there is no guarantee that it would restore renal parenchymal oxygen homeostasis. More important, 2 meta-analyses and a large double-blind, prospective, multiple-center, randomized controlled trial have failed to demonstrate that dopamine protects the kidney in critically ill patients with ARF. Currently, there is insufficient evidence to support the use of renal-dose dopamine in the intensive care unit.

Key Words: low-dose dopamine • renal-dose dopamine • acute renal failure • renal protection • renal blood flow

Journal of Intensive Care Medicine, Vol. 20, No. 4, 199-211 (2005)
DOI: 10.1177/0885066605276963


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?